Search

Your search keyword '"Paredes D."' showing total 746 results
Start Over Author "Paredes D."
746 results on '"Paredes D."'

3. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Author

Trujillo‐Santos, Javier, Farge‐Bancel, Dominique, Pedrajas, José María, Gómez‐Cuervo, Covadonga, Ballaz, Aitor, Braester, Andrei, Mahé, Isabelle, Villalobos, Aurora, Porras, José Antonio, Monreal, Manuel, Adarraga, MD, Aibar, J, Aibar, MA, Amado, C, Arcelus, JI, Asuero, A, Barba, R, Barbagelata, C, Barrón, M, Barrón‐Andrés, B, Blanco‐Molina, A, Botella, E, Camon, AM, Casado, I, Castro, J, Castro, M, Chasco, L, Criado, J, de Ancos, C, del Toro, J, Demelo‐Rodríguez, P, Díaz‐Brasero, AM, Díaz‐Peromingo, JA, Di Campli, MV, Dubois‐Silva, A, Escribano, JC, Espósito, F, Falgá, C, Farfán‐Sedano, AI, Fernández‐Capitán, C, Fernández‐Reyes, JL, Fidalgo, MA, Flores, K, Font, C, Font, L, Francisco, I, Gabara, C, Galeano‐Valle, F, García, MA, García‐Bragado, F, García de Herreros, M, García de la Garza, R, García‐Díaz, C, García‐Hernáez, R, García‐Raso, A, Gil‐Díaz, A, Giménez‐Suau, M, Grau, E, Guirado, L, Gutiérrez, J, Hernández‐Blasco, L, Hernando, E, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Jiménez, R, Jiménez‐Alfaro, C, Joya, MD, Lainez‐Justo, S, Latorre, A, Lima, J, Llamas, P, Lobo, JL, López‐Jiménez, L, López‐Miguel, P, López‐Núñez, JJ, López‐Reyes, R, López‐Sáez, JB, Lorenzo, A, Madridano, O, Maestre, A, Marchena, PJ, Martín‐Martos, F, Martínez‐Urbistondo, D, Mella, C, Mercado, MI, Moisés, J, Morales, MV, Muñoz‐Blanco, A, Muñoz‐Rivas, N, Navas, MS, Nieto, JA, Nofuentes‐Pérez, E, Núñez‐Fernández, MJ, Obispo, B, Olid, M, Olivares, MC, Orcastegui, JL, Osorio, J, Otalora, S, Otero, R, Paredes, D, Parra, P, Pellejero, G, Portillo, J, Rivera‐Civico, F, Rodríguez‐Chiaradía, DA, Rodríguez‐Matute, C, Rogado, J, Rosa, V, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Ruiz‐Ruiz, J, Ruiz‐Sada, P, Salgueiro, G, Sánchez‐Martínez, R, Sánchez‐Muñoz‐Torrero, JF, Sancho, T, Soler, S, Suárez‐Rodríguez, B, Suriñach, JM, Tirado, R, Torres, MI, Tolosa, C, Uresandi, F, Valero, B, Valle, R, Varona, JF, Vidal, G, Villares, P, Zamora, C, Engelen, M, Vanassche, T, Verhamme, P, Hirmerova, J, Malý, R, Ait Abdallah, N, Bertoletti, L, Bura‐Riviere, A, Catella, J, Couturaud, F, Crichi, B, Debourdeau, P, Espitia, O, Falvo, N, Helfer, H, Lacut, K, Le Mao, R, Moustafa, F, Poenou, G, Quere, I, Schellong, S, Brenner, B, Tzoran, I, Nikandish, R, Bilora, F, Brandolin, B, Ciammaichella, M, Di Micco, P, Imbalzano, E, Maida, R, Pace, F, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Zalunardo, B, Birzulis, J, Skride, A, Zaicenko, A, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Bounameaux, H, Mazzolai, L, Ochoa‐Chaar, CI, Weinberg, I, and Bui, HM

Published
2022
Full Text
View/download PDF

5. Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders.

Author

Yan, L, Shamir, A, Skirzewski, M, Leiva-Salcedo, E, Kwon, O, Karavanova, I, Paredes, D, Malkesman, O, Bailey, K, Vullhorst, D, Buonanno, A, and Crawley, Jacqueline

Subjects
Animals, Behavior, Animal, Brain, Clozapine, Dopamine, ErbB Receptors, Male, Mental Disorders, Mice, Mice, Knockout, Nerve Growth Factors, Neuregulin-1, Receptor, ErbB-4, Signal Transduction, Synapses, Transcriptome
Abstract

Numerous genetic and functional studies implicate variants of Neuregulin-1 (NRG1) and its neuronal receptor ErbB4 in schizophrenia and many of its endophenotypes. Although the neurophysiological and behavioral phenotypes of NRG1 mutant mice have been investigated extensively, practically nothing is known about the function of NRG2, the closest NRG1 homolog. We found that NRG2 expression in the adult rodent brain does not overlap with NRG1 and is more extensive than originally reported, including expression in the striatum and medial prefrontal cortex (mPFC), and therefore generated NRG2 knockout mice (KO) to study its function. NRG2 KOs have higher extracellular dopamine levels in the dorsal striatum but lower levels in the mPFC; a pattern with similarities to dopamine dysbalance in schizophrenia. Like ErbB4 KO mice, NRG2 KOs performed abnormally in a battery of behavioral tasks relevant to psychiatric disorders. NRG2 KOs exhibit hyperactivity in a novelty-induced open field, deficits in prepulse inhibition, hypersensitivity to amphetamine, antisocial behaviors, reduced anxiety-like behavior in the elevated plus maze and deficits in the T-maze alteration reward test-a task dependent on hippocampal and mPFC function. Acute administration of clozapine rapidly increased extracellular dopamine levels in the mPFC and improved alternation T-maze performance. Similar to mice treated chronically with N-methyl-d-aspartate receptor (NMDAR) antagonists, we demonstrate that NMDAR synaptic currents in NRG2 KOs are augmented at hippocampal glutamatergic synapses and are more sensitive to ifenprodil, indicating an increased contribution of GluN2B-containing NMDARs. Our findings reveal a novel role for NRG2 in the modulation of behaviors with relevance to psychiatric disorders.

Published
2018

6. Timing and characteristics of venous thromboembolism after noncancer surgery

Author

Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge-Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A., Bui, Hanh My, Adarraga, M.D., Agud, M., Aibar, J., Aibar, M.A., Amado, C., Arcelus, J.I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Botella, E., Camon, A.M., Campos, S., Cañas, I., Casado, I., Castro, J., Criado, J., de Ancos, C., de Miguel, J., Toro, J. del, Demelo-Rodríguez, P., Díaz-Pedroche, C., Díaz-Peromingo, J.A., Díez-Sierra, J., Domínguez, I.M., Escribano, J.C., Falgá, C., Farfán, A.I., Fernández de Roitegui, K., Fernández-Aracil, C., Fernández-Capitán, C., Fernández-Reyes, J.L., Fidalgo, M.A., Flores, K., Font, C., Font, L., Francisco, I., Furest, I., Gabara, C., Galeano-Valle, F., García, M.A., García-Bragado, F., García-Hernáez, R., García-Raso, A., Gavín-Sebastián, O., Gil-Díaz, A., Gómez-Cuervo, C., González-Martínez, J., Grau, E., Giménez-Suau, M., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Herreros, M., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jiménez, R., Joya, M.D., Jou, I., Lalueza, A., Lecumberri, R., Lima, J., Llamas, P., Lobo, J.L., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Sáez, J.B., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P.J., Martín del Pozo, M., Martín-Martos, F., Mella, C., Mellado, M., Mercado, M.I., Moisés, J., Monreal, M., Morales, M.V., Muñoz-Blanco, A., Muñoz-Guglielmetti, D., Muñoz-Rivas, N., Nieto, J.A., Núñez-Ares, A., Núñez-Fernández, M.J., Obispo, B., Olivares, M.C., Orcastegui, J.L., Ortega-Recio, M.D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J.M., Pellejero, G., Pesántez, D., Porras, J.A., Portillo, J., Riera-Mestre, A., Rivas, A., Rivera, F., Rodríguez-Cobo, A., Rodríguez-Matute, C., Rogado, J., Rosa, V., Rubio, C.M., Ruiz-Artacho, P., Ruiz-Giménez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J.C., Salgueiro, G., Sampériz, A., Sánchez-Muñoz-Torrero, J.F., Sancho, T., Sigüenza, P., Soler, S., Suriñach, J.M., Torres, M.I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Vela, J.R., Vidal, G., Villares, P., Zamora, C., Gutiérrez, P., Vázquez, F.J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Malý, R., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahé, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Bilora, F., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Di Micco, P., Grandone, E., Marchi, D., Mastroiacovo, D., Maida, R., Pace, F., Pesavento, R., Prandoni, P., Quintavalla, R., Rinzivillo, N., Rocci, A., Siniscalchi, C., Tufano, A., Visonà, A., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Krstevski, G., Bounameaux, H., Mazzolai, L., Caprini, J.A., Tafur, A.J., Weinberg, I., Wilkins, H., Bui, H.M., Expósito-Ruiz, Manuela, Arcelus, Juan Ignacio, López-Espada, Cristina, Bura-Riviere, Alessandra, Amado, Cristina, Loring, Mónica, and Mastroiacovo, Daniela

Published
2021
Full Text
View/download PDF

7. The Respiratory Physiotherapy, a New Tool to Increase the Lung Donors Pool

Author

Bello, I., primary, Ballesteros, G., additional, Garcés, B., additional, Mercabal, J., additional, Paredes, D., additional, Peñalver, M., additional, Miñambres, E., additional, Suarez, Á., additional, Gómez, A., additional, Pascual, B., additional, Sánchez-Etayo, G., additional, Martí, D., additional, Navas, E., additional, Boada, M., additional, Grando, L., additional, Dominguez-Gil, B., additional, and Sandiumenge, A., additional

Published
2024
Full Text
View/download PDF

9. R.I.S.Q: Risk Assessment Tool for Quito

Author

Jacome Polit, David, Cubillo, P., Paredes, D., Ruiz Villalba, P., Pisello, Anna Laura, Editorial Board Member, Hawkes, Dean, Editorial Board Member, Bougdah, Hocine, Editorial Board Member, Rosso, Federica, Editorial Board Member, Abdalla, Hassan, Editorial Board Member, Boemi, Sofia-Natalia, Editorial Board Member, Mohareb, Nabil, Editorial Board Member, Mesbah Elkaffas, Saleh, Editorial Board Member, Bozonnet, Emmanuel, Editorial Board Member, Pignatta, Gloria, Editorial Board Member, Mahgoub, Yasser, Editorial Board Member, De Bonis, Luciano, Editorial Board Member, Kostopoulou, Stella, Editorial Board Member, Pradhan, Biswajeet, Editorial Board Member, Abdul Mannan, Md., Editorial Board Member, Alalouch, Chaham, Editorial Board Member, O. Gawad, Iman, Editorial Board Member, Amer, Mourad, Series Editor, Elvin, George, editor, and Carracedo, Oscar, editor

Published
2019
Full Text
View/download PDF

14. Equity, Diversity and Inclusion (EDI) in Organ Transplantation: An ESOT Survey About EDI Within ESOT as an Organization and its Educational Activities, and Transplantation Research and Science

Author

Pengel, L. H. M., primary, Kaisar, M., additional, Benjamens, S., additional, Ibrahim, M., additional, Ricci, V., additional, Bellini, M. I., additional, Breithaupt-Faloppa, A. C., additional, Falk, C., additional, Maple, H., additional, Marson, L., additional, Ortiz, F., additional, Papalois, V., additional, Paredes, D., additional, and Forsberg, A., additional

Published
2023
Full Text
View/download PDF

21. Link between interlayer hybridization and ultrafast charge transfer in WS2-graphene heterostructures

Author

Hofmann, N., Weigl, L., Gradl, J., Mishra, N., Orlandini, G., Forti, S., Coletti, C., Latini, S., Xian, L., Rubio, A., Paredes, D., Causin, R., Brem, S., Malic, E., and Gierz, I.

Abstract

Ultrafast charge separation after photoexcitation is a common phenomenon in various van-der-Waals (vdW) heterostructures with great relevance for future applications in light harvesting and detection. Theoretical understanding of this phenomenon converges towards a coherent mechanism through charge transfer states accompanied by energy dissipation into strongly coupled phonons. The detailed microscopic pathways are material specific as they sensitively depend on the band structures of the individual layers, the relative band alignment in the heterostructure, the twist angle between the layers, and interlayer interactions resulting in hybridization. We used time- and angle-resolved photoemission spectroscopy combined with tight binding and density functional theory electronic structure calculations to investigate ultrafast charge separation and recombination in WS2-graphene vdW heterostructures. We identify several avoided crossings in the band structure and discuss their relevance for ultrafast charge transfer. We relate our own observations to existing theoretical models and propose a unified picture for ultrafast charge transfer in vdW heterostructures where band alignment and twist angle emerge as the most important control parameters.

Published
2023

23. Equity, Diversity and Inclusion (EDI) in Organ Transplantation:An ESOT Survey About EDI Within ESOT as an Organization and its Educational Activities, and Transplantation Research and Science

Author

Pengel, L. H.M., Kaisar, M., Benjamens, S., Ibrahim, M., Ricci, V., Bellini, M. I., Breithaupt-Faloppa, A. C., Falk, C., Maple, H., Marson, L., Ortiz, F., Papalois, V., Paredes, D., Forsberg, A., Pengel, L. H.M., Kaisar, M., Benjamens, S., Ibrahim, M., Ricci, V., Bellini, M. I., Breithaupt-Faloppa, A. C., Falk, C., Maple, H., Marson, L., Ortiz, F., Papalois, V., Paredes, D., and Forsberg, A.

Abstract

The European Society of Organ Transplantation (ESOT) strives to promote equity, diversity, and inclusion (EDI) across all its activities. We surveyed the transplant community’s experiences and perspectives regarding EDI within ESOT as an organization and its educational activities, and research in general. A total of 299 respondents completed the questionnaire. About half agreed that ESOT’s Executive Committee, Council, and Sections/Committees are diverse and inclusive (51%) and that ESOT promotes EDI in its live and digital educational activities (54%). Forty percent of respondents agreed that scientific and clinical trials in the field of transplantation are diverse and inclusive. Despite the wide distribution of the survey, most of the respondents self-identified as White and were either physician or surgeon. However, the results contribute a unique insight into the experiences and perspectives of the transplantation community regarding EDI. Whilst ESOT is committed to the principles of EDI, perceptions and the high number of proposals show the apparent need to prioritize efforts to embed EDI across ESOT and transplantation science. These data should constitute a starting point for change and provide guidance for future efforts to promote EDI within the transplantation community.

Published
2023

35. Synthesis, characterization, and evaluation of antibacterial effect of Ag nanoparticles against Escherichia coli O157:H7 and methicillin- resistant Staphylococcus aureus (MRSA)

Author

Paredes D, Ortiz C, and Torres R

Subjects
Medicine (General), R5-920
Abstract

Daissy Paredes,1 Claudia Ortiz,2 Rodrigo Torres1 1Escuela de Química, Facultad de Ciencias, Universidad Industrial de Santander, Colombia; 2Escuela de Bacteriología y Laboratorio Clínico, Facultad de Salud, Universidad Industrial de Santander, Colombia Abstract: Silver nanoparticles (AgNPs) have been shown great interest because of their potential antibacterial effect. Recently, this has been increased due to resistance in some pathogenic bacteria strains to conventional antibiotics, which has initiated new studies to search for more effective treatments against resistant microorganisms. For these reasons, AgNPs have become an important approach for applications in nanobiotechnology in the development of antibiotic treatment of different bacterial infections. This study was aimed at synthesizing AgNPs using cysteine as a reducer agent and cetyl-tri-methyl-ammonium bromide as a stabilizer in order to obtain more efficient treatment against the pathogen bacteria Escherichia coli O157:H7. These AgNPs were characterized through UV-Vis spectroscopy, transmission electron microscopy, and dynamic light scattering. From these analyses, formation of spherical nanoparticles with an average size of 55 nm was confirmed. Finally, minimal inhibitory concentration (MIC) and minimal bactericide concentration (MBC) of these AgNPs against pathogenic strains E. coli O157:H7 and methicillin-resistant Staphylococcus aureus (MRSA) were determined in both solid and liquid media. MIC and MBC values were around 0.25 µg/mL and 1 µg/mL, respectively. These parameters were comparable to those reported in the literature and were even more effective than other synthesized AgNPs. Keywords: nanomaterials, antibacterial activity, minimal inhibitory concentration, MIC, minimal bactericide concentration, MBC

Published
2014

39. List of Contributors

Author

Allen, M., primary, Bellard, E., additional, Berg, E., additional, Canevari de Paredes, D., additional, Chester-Fangman, C., additional, Courtney, M., additional, DeJonghe, J., additional, Desilets, M.R., additional, Detterbeck, K., additional, Doi, C., additional, Dumond, J., additional, Eichenholtz, S., additional, Filkins, M.M., additional, Flaccavento, M., additional, Francis, D., additional, Garber, G., additional, Getts, E., additional, Glisson, L., additional, Hagedon, M., additional, Hall, R., additional, Hess, A.N., additional, Iverson, S., additional, Judd, C., additional, Kelt, M., additional, Kline, E., additional, Kumaran, M., additional, Larson, C.M., additional, Lightfoot, D., additional, Logan, J., additional, Long, J., additional, Lucky, S., additional, Maddison, T., additional, Marcum, B., additional, Morant, B., additional, Ridlen, P., additional, Roth, A., additional, Sciangula, M., additional, Secovnie, K.O., additional, Sult, L., additional, Theissen, J.M., additional, Turnbow, D., additional, Wallace, N., additional, Webb, J., additional, and Ziegler, C., additional

Published
2017
Full Text
View/download PDF

50. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

Author

Camporese, G., Simioni, P., Di Micco, P., Fernandez-Capitan, C., Rivas, A., Font, C., Sahuquillo, J. C., Villares, P., Prandoni, P., Monreal, M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Castro, J., Caudevilla, M. A., Cerda, P., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Dominguez, I. M., Encabo, M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez de Roitegui, K., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Joya, M. D., Jou, I., Lacruz, B., Lalueza, A., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Baquerizo, C., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Munoz-Rivas, N., Nart, E., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Recio, M. D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Peris, M. L., Pesantez, D., Porras, J. A., Portillo, J., Ramos, E., Reig, L., Riera-Mestre, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rogado, J., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Siguenza, P., Sirisi, M., Soler, S., Suarez, S. Surinach J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Vilar, C., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Make, K., Meilanden, K., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J. A., Tafur, A. J., Weinberg, I., Wilkins, H., Bui, H. M., and UAM. Departamento de Medicina

Subjects
Male, medicine.medical_specialty, Time Factors, Dose, Medicina, Pyridines, Hemorrhage, General Biochemistry, Genetics and Molecular Biology, Article, chemistry.chemical_compound, Edoxaban, Recurrence, Internal medicine, medicine, Humans, Prospective Studies, Registries, General Pharmacology, Toxicology and Pharmaceutics, Long term therapy, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Tapering, business.industry, lcsh:Public aspects of medicine, General Neuroscience, Mortality rate, Research, lcsh:RM1-950, Hazard ratio, Anticoagulants, lcsh:RA1-1270, General Medicine, Articles, Venous Thromboembolism, Middle Aged, Confidence interval, Thiazoles, lcsh:Therapeutics. Pharmacology, chemistry, Practice Guidelines as Topic, Dose reduction, Female, business, Venous thromboembolism, Follow-Up Studies
Abstract

Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8.37; 95% confidence interval (CI) 1.12–42.4) and a significant higher mortality rate (HR 31.1; 95% CI 4.63–262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5.04; 95% CI 0.54–133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated., No funding was received for this work

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results